PBYI · Puma Biotechnology, Inc. · Investor Relations

$10.64 -0.28 (-2.58%) Q2 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$563.69M

51.62M

Volume · Oct 28 418.45K Avg daily vol (3M) 330.59K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date	Event	Type
2026-11-05 00:00 UTC	November 5, 2026 - Puma Biotechnology 3Q-2026 Financial Results Conference Call	Earnings call

Past events

Date	Event	Type
2026-10-22	Oct. 22, 2026 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results	Earnings call
2026-09-17	Sept. 17, 2026 - Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer	Event
2026-09-14	Sept. 14, 2026 - H.C. Wainwright 28th Annual Global Investment Conference	Conference
2026-09-09	Sept. 9, 2026 - Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference	Conference
2026-08-06	August 6, 2026 - Puma Biotechnology 2Q-2026 Financial Results Conference Call	Earnings call
2026-08-06	Aug. 6, 2026 - Puma Biotechnology Reports Second Quarter 2026 Financial Results	Results publication
2026-07-23	July 23, 2026 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results	Earnings call
2026-06-11	June 11, 2026	Event
2026-05-07	May 7, 2026 - Puma Biotechnology 1Q-2026 Financial Results Conference Call	Earnings call
2026-05-07	Puma Biotechnology 1Q-2026 Financial Results Conference Call	Earnings call
2026-02-26	Earnings conference call (announced in 8-K)	Earnings call

Source: https://investor.pumabiotechnology.com/

Key facts CIK 1401667 CUSIP 74587V107 13F (30d) 31 filings 31 filers Visit website Investor relations